Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Stahl, Stephen M.
2014.
Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
CNS Spectrums,
Vol. 19,
Issue. 6,
p.
475.
Pringle, Abbie
Bogdanovskaya, Maria
Waskett, Poppy
Zacharia, Sophie
Cowen, Philip J
and
Harmer, Catherine J
2015.
Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
Journal of Psychopharmacology,
Vol. 29,
Issue. 10,
p.
1129.
De Berardis, Domenico
Fornaro, Michele
Serroni, Nicola
Campanella, Daniela
Rapini, Gabriella
Olivieri, Luigi
Srinivasan, Venkataramanujam
Iasevoli, Felice
Tomasetti, Carmine
De Bartolomeis, Andrea
Valchera, Alessandro
Perna, Giampaolo
Mazza, Monica
Di Nicola, Marco
Martinotti, Giovanni
and
Di Giannantonio, Massimo
2015.
Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression.
International Journal of Molecular Sciences,
Vol. 16,
Issue. 1,
p.
1111.
Tchekalarova, Jana
Moyanova, Slavianka
Fusco, Antonio De
and
Ngomba, Richard Teke
2015.
The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders.
Brain Research Bulletin,
Vol. 119,
Issue. ,
p.
80.
Anderson, George
and
Maes, Michael
2015.
The gut–brain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions.
Advances in Integrative Medicine,
Vol. 2,
Issue. 1,
p.
31.
Englisch, Susanne
Jung, Hanna Sophie
Lewien, Antje
Becker, Anna
Nowak, Ulrike
Braun, Hanna
Thiem, Jascha
Eisenacher, Sarah
Meyer-Lindenberg, Andreas
and
Zink, Mathias
2016.
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders.
Journal of Clinical Psychopharmacology,
Vol. 36,
Issue. 6,
p.
597.
Medvedev, V. E.
Retiunsky, K. Yu.
Ovchinnikov, A. A.
Barylnik, Yu. B.
Shmilovich, A. A.
Antokhin, E. Yu.
Usov, G. M.
Cheremin, R. A.
Poletsky, V. M.
Onegin, A. V.
Kireeva, I. P.
Frolova, V. I.
Filippova, N. V.
Antonova, A. A.
Deeva, M. A.
and
Onegina, D. A.
2016.
The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study “EMOTSIA”).
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova,
Vol. 116,
Issue. 11,
p.
26.
Gargoloff, Pedro Damian
Corral, Ricardo
Herbst, Luis
Marquez, Miguel
Martinotti, Giovanni
and
Gargoloff, Pedro Rafael
2016.
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.
Human Psychopharmacology: Clinical and Experimental,
Vol. 31,
Issue. 6,
p.
412.
Tchekalarova, Jana
Atanasova, Dimitrinka
Nenchovska, Zlatina
Atanasova, Milena
Kortenska, Lidia
Gesheva, Rumyana
and
Lazarov, Nikolai
2017.
Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy.
Neurobiology of Disease,
Vol. 104,
Issue. ,
p.
1.
Thase, Michael E.
Danchenko, Natalya
Brignone, Melanie
Florea, Ioana
Diamand, Francoise
Jacobsen, Paula L.
and
Vieta, Eduard
2017.
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
European Neuropsychopharmacology,
Vol. 27,
Issue. 8,
p.
773.
Medvedev, V. E.
Retyunskii, K. Yu.
Ovchinnikov, A. A.
Baryl’nik, Yu. B.
Shmilovich, A. A.
Antokhin, E. Yu.
Usov, G. M.
Cheremin, R. A.
Poletskii, V. M.
Onegin, A. V.
Kireeva, I. P.
Frolova, V. I.
Filippova, N. V.
Antonova, A. A.
Deeva, M. A.
and
Onegina, D. A.
2018.
Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial).
Neuroscience and Behavioral Physiology,
Vol. 48,
Issue. 3,
p.
367.
Muneer, Ather
2018.
Understanding Depression.
p.
15.
Tchekalarova, Jana
Atanasova, Dimitrinka
Kortenska, Lidia
Lazarov, Nikolai
Shishmanova-Doseva, Michaela
Galchev, Tzeno
and
Marinov, Pencho
2019.
Agomelatine alleviates neuronal loss through BDNF signaling in the post-status epilepticus model induced by kainic acid in rat.
Brain Research Bulletin,
Vol. 147,
Issue. ,
p.
22.
Lee, Jung Goo
Woo, Young Sup
Park, Sung Woo
Seog, Dae-Hyun
Seo, Mi Kyoung
and
Bahk, Won-Myong
2019.
The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease.
Brain Sciences,
Vol. 9,
Issue. 10,
p.
285.
Saiz-Rodríguez, Miriam
Ochoa, Dolores
Belmonte, Carmen
Román, Manuel
Vieira de Lara, Danilo
Zubiaur, Pablo
Koller, Dora
Mejía, Gina
and
Abad-Santos, Francisco
2019.
Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.
Journal of Psychopharmacology,
Vol. 33,
Issue. 4,
p.
522.
Ethemoglu, M.S.
Kutlu, S.
Seker, F.B.
Erdogan, C.S.
Bingol, C.A.
and
Yilmaz, B.
2019.
Effects of agomelatine on electrocorticogram activity on penicillin-induced seizure model of rats.
Neuroscience Letters,
Vol. 690,
Issue. ,
p.
120.
Ilieva, Kalina
Tchekalarova, Jana
Atanasova, Dimitrinka
Kortenska, Lidia
and
Atanasova, Milena
2019.
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Hormones and Behavior,
Vol. 107,
Issue. ,
p.
11.
Bromek, Ewa
Rysz, Marta
Haduch, Anna
and
Daniel, Władysława A.
2019.
Stimulation of 5-HT2C serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver.
Pharmacological Reports,
Vol. 71,
Issue. 6,
p.
1210.
2020.
Prescriber's Guide.
p.
5.
Stahl, Stephen M.
2020.
Prescriber's Guide.